Skip to main
VERU

Veru (VERU) Stock Forecast & Price Target

Veru (VERU) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Veru Inc. is positioned well within the expanding biopharmaceutical market, particularly given the promising outcomes from recent GLP-1 clinical trials, which may lead to an accelerated growth trajectory for similar therapies due to their beneficial impacts on weight loss and reduced health risks. The significant market opportunity in muscle preservation and obesity treatment is underscored by the explosive growth of competitors' revenue, exemplified by Zepbound's sales increasing from $2.3 billion in 1Q25 to $3.6 billion in 3Q25, indicating strong market demand and potential for Veru's offerings. Furthermore, the dramatic rise in global spending on obesity medications, from approximately $3 billion in 2020 to over $30 billion by 2024, reflects a substantial and growing market that Veru could tap into with its innovative drug development programs.

Bears say

Veru Inc. faces significant risks related to the potential failure of its development programs, which can severely hamstring future revenue growth and lead to a decline in stock value. The company is also navigating intense competition that may pressure revenue expectations and escalate regulatory hurdles impacting drug approval chances. Additionally, high turnover in key regulatory roles such as CEO and CMO raises concerns about the company's strategic stability and could further negatively impact share performance.

Veru (VERU) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veru (VERU) Forecast

Analysts have given Veru (VERU) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Veru (VERU) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veru (VERU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.